Street Calls of the Week
Volitionrx LTD (NASDAQ:VNRX) President and CEO Cameron John Reynolds has purchased 15,000 shares of the company’s common stock at a price of $0.659 per share, for a total transaction value of $9,885. The purchase comes as the $70.6 million market cap company trades below its InvestingPro Fair Value, with analyst price targets ranging from $2 to $5 per share suggesting significant upside potential.
The transaction, which took place on September 12, 2025, was disclosed in a Form 4 filing with the Securities and Exchange Commission. Following the purchase, Reynolds directly owns 2,624,847 shares of Volitionrx LTD. He also indirectly owns 1,007,718 shares through Concord International, Inc., where he is the majority shareholder, and 34,076 shares are held by his spouse. For deeper insights into insider trading patterns and comprehensive financial analysis, including 8 key ProTips about VNRX’s financial health, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, VolitionRx Limited reported a 15% year-over-year revenue increase for Q2 2025, reaching over $400,000. Despite the revenue growth, the company highlighted a reduction in net cash usage in operating activities and emphasized a strategic focus on achieving cash neutrality by the end of 2025. Additionally, VolitionRx announced a significant partnership with Werfen’s Immunoassay Technology Center, signing a Research License and Exclusive Commercial Option Rights Agreement. This agreement allows Werfen to access components of Volition’s proprietary Nu.Q H3.1 NETs assay for Antiphospholipid Syndrome testing. Werfen, a leader in in vitro diagnostics with $2.2 billion in revenue in 2024, also secured the option to negotiate terms for a potential commercial launch under an exclusive license. In light of these developments, H.C. Wainwright reiterated its Buy rating on VolitionRx, maintaining a price target of $2.50.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.